Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.

BMC cancer - 23 Nov 2012

Pelttari Liisa M, Nurminen Riikka, Gylfe Alexandra, Aaltonen Lauri A, Schleutker Johanna, Nevanlinna Heli

Abstract excerpt

BACKGROUND: Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer. Risk for other cancers has not been studied. METHODS: To study the role of RAD51C mutations in other common cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Finland

Share to Founder Effect

Share to Genetic Predisposition to Disease

Share to Genotype

Share to Mutation

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23176254
DOI: 10.1186/1471-2407-12-552
PMCID: PMC3522023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.PMID 23176254Read ↗

RAD51C is a susceptibility gene for ovarian cancer.Semantic proximity Read ↗

A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.Semantic proximity Read ↗

Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.Semantic proximity Read ↗

Genetic testing for RAD51C mutations: in the clinic and community.Semantic proximity Read ↗

Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.Semantic proximity Read ↗

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.Semantic proximity Read ↗

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patientsSemantic proximity Read ↗

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.Semantic proximity Read ↗

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.Semantic proximity Read ↗

Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.Semantic proximity Read ↗

Germline RAD51C mutations in ovarian cancer susceptibility.Semantic proximity Read ↗

RAD51B in Familial Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.